I'm assuming the drug you're talking about with "serious safety issues" is sparsentan rather than DXB200? If so I'm confused by that assertion because if you look at both published pivotal phase 3 trials for sparsentan in IgA nephropathy and FSGS, nearly 800 patients collectively, there weren't any serious safety concerns reported, indeed in both trials sparsentan and its comparator irbestartan showed comparable safety results and we all know irbesartan is safe. I'd argue that sparsentan safety information is better characterised and more certain than that of DXB200 at this stage by virtue of the simple fact it's been trialled in so many more patients over an extended period (2 years +) and now on market. Not downplaying DXB, just stating a fact about another drug.
Speaking of market, interesting slide from Travere presentation showing all their tie-ups across the globe in IgA nephropathy, including Asia.
DXB Price at posting:
48.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)